Read More

K36 Therapeutics Announces $70M Series B Financing To Fund Clinical Proof Of Concept Of KTX-1001, First-In-Class Inhibitor Of MMSET For Treatment Of Multiple Myeloma Patients With Genetic Translocation (4;14)

 Funds raised will be used to demonstrate clinical validation and proof-of-concept in t(4;14) multiple myeloma with KTX-1001 monotherapy and KTX-1001 combination regimens with existing standard-of-care

BMY